- Neuberg Diagnostics
completed merger of Supratech
- Biocon acquires Eywa
Pharma's US-based plant.
- Sun Pharma inks
agreement with US-based Pharmazz on cerebral ischemic stroke drug
Sovateltide to market in India using the brand name Tyvalzi™
(Sovateltide).
- Cosmo Pharmaceuticals,
Glenmark sign distribution, license agreements for Winlevi in
Europe, South Africa.
- Sun Pharma to buyout
local partner in Mexican arm.
- Cipla to acquire South
Africa-based Actor Pharma.
- Biocon Biologics
completes integration of Viatris biosimilars business in North
America.
- Lupin has collaborated
with Mark Cuban Cost Plus Drug Company and the COPD Foundation to
expand the availability of a generic drug in the US.
- BioNTech partners with
CEPI to advance development of mpox vaccine. CEPI will provide
funding of up to US$90 million to support vaccine candidates based
on BioNTech's mRNA technology.
- Salipro Biotech enters
collaboration with Sumitomo Pharma.
- Dynamic Code has
acquired the bankrupt FindOut Diagnostic
- Devyser and Thermo
Fisher Scientific have agreed to expand commercial collaboration.
- Moderna ties up with
Immatics to boost cancer vaccine development.
- Evaxion enters
prophylactic vaccine partnership with Afrigen Biologics.
|
- Aagami to attend BIO
JAPAN 2023 in Yokohama, Japan (Oct 11-13) followed by a road show
Oct (16-17) to promote client’s market ready Denosumab biosimilar.
CEO Dinesh Jain, fluent in Japanese language, will join client
leadership for the trip.
- This time Bio-Europe is
in Munich, Germany (Nov 6-8). Like every year, Aagami is
attending. Vice-President Godwyn Francis will represent Aagami and
its clients during the partnering conference.
|
|
|
|
|
INFOCUS: Select opportunities available at Aagami:
|
|
|
|
|
|
For Partnering/Licensing/ Co-development:
- Licensing available for
Japan: Market
ready Denosumab biosimilar to PROLIA® & XGEVA®.
- Seeking Partnering/JV – Smart Drug
preventing Myelodysplastic Syndromes (MDS) from advancing to
full-scale myelogenous Leukemia (Second Human Trial ongoing in
AU).
For Acquisition:
- Available at a very
reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology,
product candidates, data package of ~20 drug candidates, IP etc.-
for Next-generation biologics and substantial returns.
- Asset Sale - Oral small molecule
oral small molecule modulator of mutant RyR2 for the treatment of
CPVT-1/ Heart Arrhythmia. California based
- Asset sale –US client’s Smart
Drug preventing Myelodysplastic Syndromes (MDS) from advancing to
full-scale myelogenous Leukemia (Second Human Trial ongoing in
AU).
Seeking Investment:
- Seeking US$15 million
for Phase-1 POC: Intranasal Rifampicin (Patented, Orphan Drug
Designation) for neurodegenerative diseases (High ROI).
- Seeking US$5 million: A single (monovalent)
vaccine for Targeting Salmonella, ETEC / E. coli,
Campylobacter, Shigella. Fulfills an unmet need for treating
Bacterial Dysentery.
- Seeking US$5 million: Midwest US based Pharma
with Phase 2 stage First-in-Class Non-Opioid Analgesic NCE for
Pain Relief.
|
|
|
|
|
|
|
|